Adrenal Cortex Neoplasms

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-03-11
EMA Authorised: Lysodren (mitotane) — Esteve Pharmaceuticals, S.A.
EMA authorised marketing of Lysodren (mitotane) by Esteve Pharmaceuticals, S.A. for adrenal cortex neoplasms.